RNAi-Based GluN3A Silencing Prevents and Reverses Disease Phenotypes Induced by Mutant huntingtin
Open Access
- 1 August 2018
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 26 (8) , 1965-1972
Abstract
No abstract availableKeywords
Funding Information
- Centro de Investigación Médica Aplicada, Universidad de Navarra
- Ministerio de Ciencia e Innovación (CSD2008-00005, SAF2013-48983-R, SAF2016-80895-R, SEV-2013-0317)
- Fundación Caja Navarra
- Fundació la Marató de TV3
This publication has 33 references indexed in Scilit:
- Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse BrainPLOS ONE, 2013
- Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin SynthesisNeuron, 2012
- Assessment of Motor Balance and Coordination in Mice using the Balance BeamJournal of Visualized Experiments, 2011
- Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysisThe Lancet Neurology, 2011
- Early synaptic pathophysiology in neurodegeneration: insights from Huntington's diseaseTrends in Neurosciences, 2010
- Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtinNature Medicine, 2009
- Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease MiceMolecular Therapy, 2009
- Sustained effects of nonallele‐specific Huntingtin silencingAnnals of Neurology, 2009
- Expanded Repertoire of AAV Vector Serotypes Mediate Unique Patterns of Transduction in Mouse BrainMolecular Therapy, 2008
- Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Associated with Enkephalinergic Neuronal Degeneration in Huntington's DiseaseJournal of Neuroscience, 2004